Bayer Aktiengesellschaft BAYRY
Set alert
As of Nov 2, 10:00 AM ET
- YTD
- +29.30%
- 1 year
- +80.52%
- Open
- 13.94
- Prev close
- 13.99
- Mkt cap
- 54.98B
- Vol
- 19.20K
- Avg vol
- 605.31K
- EPS
- -0.51
- P/E
- 0.00
More statistics
- Low
- 13.93
- High
- 13.99
- Earnings
- Nov 3, 2026
5D chart
Signals (54)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:20 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:30 PM | 3 days ago |
| RSI: Overbought | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:45 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:10 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 6 days ago |
| MACD: Buy Signal | Oct 27, 10:15 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:00 AM | 6 days ago |
| RSI: Oversold | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 6 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 1 week ago |
| SMA: Bullish | Oct 26, 10:20 AM | 1 week ago |
News
1 week ago wsj.com
Bayer Gets in China Its First Global Approval for Stroke Prevention Drug
The decision hands Bayer the first ever approval for a Factor XIa inhibitor, which aim to slow the activity of a protein that regulates how the body forms clots without increasing the risk of…
2 weeks ago seekingalpha.com
Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk
Bayer (OTCPK:BAYZF) remains a long-term Buy, with the stock still undervalued despite ongoing litigation and high debt levels. Litigation risks are easing, with a major Supreme Court win and a key…
3 weeks ago businesswire.com
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart…
3 weeks ago zacks.com
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
3 weeks ago businesswire.com
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's…
3 weeks ago businesswire.com
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA®…
3 weeks ago zacks.com
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Bayer Aktiengesellschaft (BAYRY) or Roche Holding AG (RHHBY). But which of these two companies is…
1 month ago wsj.com
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.
1 month ago reuters.com
Bayer to invest $2.2 billion in new US pharma site
Bayer's pharmaceuticals unit on Friday unveiled plans to invest $2.2 billion in a new manufacturing site in New Albany, Ohio, part of a push to boost the business's US revenue.
1 month ago businesswire.com
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven…
1 month ago reuters.com
Bayer faces trial test of remaining Roundup claims after US Supreme Court win
Attorneys for three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately test its Roundup weedkiller before selling it, starting a trial that could help…
1 month ago wsj.com
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
1 month ago zacks.com
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
1 month ago businesswire.com
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio…
1 month ago reuters.com
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement
Bayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, saying there is no other way…
1 month ago reuters.com
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular…
1 month ago businesswire.com
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The…
1 month ago zacks.com
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.
1 month ago businesswire.com
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.
1 month ago businesswire.com
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
MONHEIM, Germany & ST. LOUIS--(BUSINESS WIRE)--Bayer and Neste, the world's leading producer of renewable diesel and sustainable aviation fuel, have finalized a commercial agreement to jointly scale…
5 months ago benzinga.com
Deal Dispatch: J.M. Smucker Considers Strategic Review, Meta Buys Assured Robot Intelligence, Buzzfeed On Brink Of Bankruptcy
Major M&A deals this week include: Gamestop's proposal to acquire eBay, Long Lake buys American Express Global Travel for $6.3 billion.
8 months ago benzinga.com
Trump Invokes Defense Act For Monsanto Chemicals: Bayer, Agribusiness ETFs In Focus On New Critical Mineral Status For Phosphorus
Trump invokes DPA to secure phosphorus, labeling Monsanto-produced chemicals a national defense asset. See the impact on Bayer & Ag ETFs.
-
11 months ago benzinga.com
Evotec And Bayer Kidney Disease Collaboration Advances SEMA3A Monoclonal Antibody Program Into Phase 2 Clinical Development
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026
-
2 years ago benzinga.com
Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds
Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from…
-
2 years ago benzinga.com
Top Stocks, Sectors Loved By Congress Members Who Traded In 2023: Apple, NVIDIA, Microsoft, Ford And More Stocks To Watch In 2024
One of the hottest topics among members of Congress and investors has been the stock and options trading activity by several politicians.
-
3 years ago benzinga.com
Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts
Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts
-
6 years ago benzinga.com
Stock Market Update For The Week Ahead: 'How Long Can Tech Lead?'
The Last Week In A Nutshell
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday